Abstract.
Gaucher disease is an autosomal recessive trait and the most common lysosomal storage disease. The pathogenesis evolves from the diminished activity of the lysosomal hydrolase, acid β-glucosidase and the resultant accumulation of glucosylceramide within lysosomes. The pathogenic mechanisms are poorly understood. During the past 2 decades, progress has been made in understanding the biochemical basis and molecular biology of the disease, but more fundamental knowledge is required to relate these advances to the cell and whole body phenotypes. Despite this lack of understanding, enzyme replacement therapy has proved a successful and effective management for Gaucher disease. However, basic details of this therapeutic efficacy require elucidation. Here, we review the current state of the molecular pathogenesis and provide our perspective of some major issues for continued advances in this prototype lysosomal storage disease.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received 25 October 2001; received after revision 3 December 2001; accepted 3 December 2001
Rights and permissions
About this article
Cite this article
Zhao, H., Grabowski, G. Gaucher disease: perspectives on a prototype lysosomal disease. CMLS, Cell. Mol. Life Sci. 59, 694–707 (2002). https://doi.org/10.1007/s00018-002-8458-y
Issue Date:
DOI: https://doi.org/10.1007/s00018-002-8458-y